Treatment for IMD in patients with HER2-positive breast cancer has historically been limited to surgical resection and radiotherapy; the role for chemotherapy has generally been disappointing.17–20 The intracranial efficacy of chemotherapy is thought to be limited by cell-intrinsic resistance and poor penetration of drugs across the blood–brain barrier.16,20. This evidence concerns the gene ERBB2 and breast carcinoma.